Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

General Transcription Factors01:30

General Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Transcription Factors02:16

Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep dynamical models of single-cell multiomic velocities predict loss-of-function and rescue perturbations in B cells.

bioRxiv : the preprint server for biology·2026
Same author

Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.

Haematologica·2026
Same author

Favourable 16-year outcome of an acetabular reinforcement ring with suboptimal host-bone coverage: the role of biological and mechanical stabilisation.

Journal of surgical case reports·2026
Same author

DNA methylation reprogramming in marsupial embryos is restricted to the extraembryonic lineage.

Nature communications·2026
Same author

Challenges in Diagnosing High-grade B-cell Lymphoma, NOS: Poor Interobserver Agreement on Its Morphologic Definition-An LLMPP Study.

The American journal of surgical pathology·2026
Same author

Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response.

Blood cancer journal·2026
Same journal

Targeting Cystine Addiction Suppresses Breast Cancer Lung Metastasis.

Cancer research·2026
Same journal

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

Cancer research·2026
Same journal

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

Cancer research·2026
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
See all related articles

Related Experiment Video

Updated: Jul 5, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Sequential transcription factor targeting for diffuse large B-cell lymphomas.

Leandro C Cerchietti1, Jose M Polo, Gustavo F Da Silva

  • 1Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Cancer Research
|May 3, 2008
PubMed
Summary
This summary is machine-generated.

Targeting the BCL6 repressor with BPI triggers a p53 response in diffuse large B-cell lymphomas (DLBCL). Sequential BCL6 and p53 inhibition offers a potent anti-lymphoma therapy by restoring p53 target gene expression.

More Related Videos

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

Related Experiment Videos

Last Updated: Jul 5, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Transcription factors are key drivers of cancer, regulating genes vital for cell growth and survival.
  • The BCL6 transcriptional repressor is implicated in diffuse large B-cell lymphomas (DLBCL) pathogenesis.
  • BCL6 influences critical cellular checkpoints, including the p53 tumor suppressor pathway.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting BCL6 in DLBCL.
  • To determine if BCL6 inhibition can restore p53 pathway activity.
  • To evaluate combination therapies involving BCL6 and p53 modulation.

Main Methods:

  • Utilized a specific BCL6 inhibitor (BPI) in DLBCL cell models.
  • Assessed p53 activity and expression of p53 target genes.
  • Investigated sequential treatment with BCL6 and p53 modulators.

Main Results:

  • BPI induced a p53 response in DLBCL cells, partly by increasing p53 activity and relieving BCL6 repression of p53 targets.
  • A p53-like response was observed even with mutant p53.
  • Combined BCL6 and p53 inhibition demonstrated a synergistic anti-lymphoma effect.

Conclusions:

  • Targeting BCL6 with BPI can reactivate the p53 pathway in DLBCL.
  • Sequential inhibition of BCL6 and p53 represents a promising therapeutic strategy for lymphoma.
  • Restoring overlapping BCL6 and p53 transcriptional programs may correct aberrant survival pathways in DLBCL.